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Abstract
© 2017  Nailya  Kubysheva  et  al.  The  definition  of  new  markers  of  local  and  systemic
inflammation of chronic obstructive pulmonary disease (COPD) is one of the priority directions in
the  study  of  pathogenesis  and  diagnostic  methods  improvement  for  this  disease.  We
investigated 91 patients with COPD and 21 healthy nonsmokers. The levels of soluble CD25,
CD38, CD8, and HLA-I-CD8 molecules in the blood serum and exhaled breath condensate (EBC)
in moderate-to-severe COPD patients during exacerbation and stable phase were studied. An
unidirectional change in the content of sCD25, sCD38, and sCD8 molecules with increasing
severity of COPD was detected. The correlations between the parameters of lung function and
sCD8, sCD25, and sHLA-I-CD8 levels in the blood serum and EBC were discovered in patients
with  severe  COPD.  The  findings  suggest  a  pathogenetic  role  of  the  investigated  soluble
molecules of the COPD development and allow considering the content of sCD8, sCD25, and
sHLA-I-CD8  molecules  as  additional  novel  systemic  and  endobronchial  markers  of  the
progression of chronic inflammation of this disease.
http://dx.doi.org/10.1155/2017/8216723
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